Your AI-Trained Oncology Knowledge Connection!
CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to discuss the benefit of treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone and the population of patients with newly diagnosed myeloma who will best benefit from treatment.
A retrospective review identified that clinical practice patterns have changed from 2002 to 2020, with the use of immunotherapy increasing as chemotherapy and radiation therapy use has decreased for patients with Merkel cell carcinoma.
Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, discussed the phase 2/3 EMPIRE-1 trial focusing on 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy for patients with prostate cancer.
Scott Tagawa, MD, MS, detailed 2 presentations from ESMO’s presidential symposium that he thinks will have an impact on treating patients with metastatic castration-sensitive prostate cancer.
Patients with high-risk smoldering myeloma who were treated with carfilzomib, lenalidomide, and dexamethasone and lenalidomide maintenance experienced an improvement in minimal residual disease–negative complete response and could have delayed end-organ disease.
Sintilimab with or without a bevacizumab biosimilar injection, combined with chemotherapy yielded promising findings in a population of patients with EGFR-mutant nonsquamous non–small cell lung cancer who have previously been treated with an EGFR tyrosine kinase inhibitor.
In an interview with CancerNetwork, Yazeed Sawalha, MD, discussed how socioeconomic factors can affect use of autologous stem cell transplant in multiple myeloma and lead to disparities.
The Society for Immunotherapy of Cancer published clinical practice guidelines for treating patients with breast cancer using immunotherapy.
There remains a therapeutic challenge with understanding and treating patients with accelerated myeloproliferative neoplasms.
CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk survival and progression outcomes from the CARD trial in patients with metastatic castration-resistant prostate cancer.
Patients with unresectable hepatocellular carcinoma appeared to benefit from treatment with durvalumab and tremelimumab, according to findings from the phase 3 HIMALAYA trial.
The FDA approved atezolizumab for treatment of stage II to IIIA non–small cell lung cancer following resection and platinum-based chemotherapy.
The FDA has given the Ki-67 IHC MIB-1 pharmDx assay a companion diagnostic approval for detecting Ki-67 expression in patients with high-risk early breast cancer who are being considered for treatment with abemaciclib.
CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about minimal residual disease and its importance in the treatment of multiple myeloma.
Patients with recurrent/metastatic head and neck squamous cell carcinoma and a PD-L1 combined positive score of 1 or more and 20 or more experienced a clinical benefit with first-line nivolumab plus ipilimumab compared with the EXTREME regimen.
As treatment for T-cell non-Hodgkin lymphomas continues to expand, disparities and inequities continue to grow for those within certain racial groups and of a certain socioeconomic status.
The addition of temozolomide to vincristine and irinotecan appears to be a new standard of care for adult and pediatric patients with relapsed/refractory rhabdomyosarcoma, according to the European Paediatric Soft Tissue Sarcoma Group.
Treatment with stereotactic ablative radiotherapy yielded non-inferior long-term survival compared with video-assisted thoracoscopic surgical lobectomy with mediastinal lymph node dissection in operable stage IA non–small cell lung cancer.
CancerNetwork® sat down with Edward B. Garon, MD, at the 2021 World Conference on Lung Cancer to talk about key findings with datopotamab deruxtecan therapy in patients with non–small cell lung cancer and other ongoing trials.
CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to discuss how a hypothetical cohort from the CARD trial highlighted the impact of treatment with cabazitaxel on costs and complications in patients with metastatic castration-resistant prostate cancer.
Findings from the phase 1 CARBON trial indicated that patients with relapsed/refractory CD19-positive B-cell malignancies may benefit from CTX110 CAR T-cell therapy.
The FDA has approved the use of pembrolizumab plus chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer who have PD-L1 expression identified via an FDA-approved test.
Based on a subgroup analysis from the monarchE trial, the FDA approved abemaciclib as adjuvant therapy in women with high-risk early breast cancer
Investigators identified a correlation between financial toxicity significant differences in mental and physical quality of life, and patient satisfaction with breast reconstruction among patients with breast cancer.
Results from a cohort study found that the rate of late mortality has decreased over the last 40 years for patients who transplantation at a younger age or who received a bone marrow transplant.
Patients with colorectal liver metastases who were treated with transarterial Yttrium-90 radioembolization plus second-line chemotherapy experienced a long-term survival benefit.
Clinical trials featuring rusfertide may resume dosing patients after the FDA lifted a full clinical hold on the therapy’s clinical studies.
Caron A. Jacobson, MD, MMSC, highlights data supporting the use of CAR T-cell therapy in patients with indolent lymphoma.
On this week’s podcast, Jun Gong, MD, spoke with CancerNetwork® about the potential role of plasma glutamine as a biomarker for patients with localized prostate cancer.
The phase 1b/2 CARTIRUDE-1 study found deep and durable responses, along with a tolerable safety profile with the recommended phase 2 dose of ciltacabtagene autoleucel for patients with relapsed or refractory multiple myeloma.
